NAUT · Nautilus Biotechnology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $41.11M | $50.48M | $47.25M | $37.67M | $12.43M | - |
| SG&A | $25.73M | $31.00M | $28.90M | $25.95M | $3.31M | - |
| Total Operating Expenses | $66.84M | $81.48M | $76.15M | $63.62M | $15.74M | - |
| D&A | $1.70M | $1.98M | $1.85M | $1.22M | $710.0K | - |
| Operating Income | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | ($59.00M) | ($70.78M) | ($63.67M) | ($57.92M) | ($15.62M) | - |
| EPS - Basic | ($0.47) | ($0.56) | ($0.51) | ($0.46) | ($0.54) | - |
| EPS - Diluted | ($0.47) | ($0.56) | ($0.51) | ($0.46) | ($0.54) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.39M | $27.65M | $19.40M | $114.52M | $185.62M | $1.00M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $943.0K | $987.0K | $1.64M | $1.27M | $1.72M | - |
| Current Assets | $105.96M | $132.83M | $176.84M | $187.21M | $349.22M | $1.30M |
| Total Assets | $191.11M | $242.74M | $305.56M | $350.05M | $398.45M | $150.86M |
| Current Liabilities | $7.95M | $7.63M | $9.12M | $6.79M | $5.81M | $388.5K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $34.14M | $34.01M | $40.21M | $35.13M | $34.87M | $5.62M |
| Stockholders' Equity | $156.97M | $208.73M | $265.35M | $314.92M | $363.58M | $5.00M |
| Retained Earnings | ($332.02M) | ($273.02M) | ($202.24M) | ($138.56M) | ($80.64M) | ($523.1K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($50.70M) | ($59.15M) | ($51.71M) | ($45.81M) | ($14.00M) | - |
| Investing Cash Flow | $35.22M | $66.25M | ($43.73M) | ($25.74M) | ($25.28M) | - |
| Financing Cash Flow | $214.0K | $1.14M | $368.0K | $562.0K | $75.90M | - |
| CapEx | $1.28M | $2.12M | $2.44M | $2.32M | $921.0K | - |
| Free Cash Flow | ($51.97M) | ($61.27M) | ($54.15M) | ($48.13M) | ($14.92M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.88 | 0.87 | 0.85 | 0.83 | 0.96 | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -30.9% | -29.2% | -20.8% | -16.5% | -3.9% | - |
| Return on equity | -37.6% | -33.9% | -24.0% | -18.4% | -4.3% | - |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 13.33 | 17.40 | 19.39 | 27.57 | 60.09 | 3.36 |
| Quick ratio | 13.33 | 17.40 | 19.39 | 27.57 | 60.09 | 3.36 |
| Cash ratio | 1.56 | 3.62 | 2.13 | 16.86 | 31.94 | 2.58 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.22 | 1.16 | 1.15 | 1.11 | 1.10 | 30.17 |
| Liabilities / Assets | 0.18 | 0.14 | 0.13 | 0.10 | 0.09 | 0.04 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.6x | 1.0x | 1.4x | 0.7x | 0.4x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - |
| Net income growth (YoY) | 16.6% | -11.2% | -9.9% | -270.9% | - | - |
| EPS growth (YoY) | 16.1% | -9.8% | -10.9% | 14.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 15.2% | -13.1% | -12.5% | -222.7% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -24.8% | -21.3% | -15.7% | -13.4% | 7171.5% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Nautilus Biotechnology against the 5 most active filers in the same SIC group.